en · de · es · fr · pt
hplc-notes.peptides4088.com › Guide › Research History And Clinical Assessment — Background and Details

Research History And Clinical Assessment — Background and Details

By Editorial Desk · published 2026-02-25 · last reviewed 2026-03-19 · Guide

If you have been reading about immunomodulatory peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-03-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

Research History and Clinical Assessment

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.

Storage, Handling and Analytical Verification

Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.

Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.

Thymosin-alpha-1 at a glance

PropertyValueNotes
First described1977Reported as a component of thymosin fraction 5
Sequence length28 amino acidsN-terminal residue is acetylated
Net charge at neutral pHNegativeReflects a high proportion of acidic residues
Principal studied usesChronic hepatitis B and vaccine adjuvantResearch uses outnumber approved indications
Regulatory statusApproved in a limited number of countriesNot approved in the United States or most of Europe

Background and Molecular Profile

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

Related pages on this site

免疫调节机制与信号

临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善,但临床终点获益在不同研究中并不一致。系统综述指出,研究间在人群、剂量和联合方案上差异较大,难以汇总结论。因此,Tα1的确切临床地位仍属开放问题,需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。

胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明,它可促进未成熟T细胞向成熟T细胞分化,并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子,从而更有效地呈递抗原。此外,自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体,而是调节宿主免疫应答的强度与方向。

Molecular Identity Of Thymosin Alpha-1

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Analytical Methods and Storage Stability

Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.

Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.

Further detail

The cell's energy is equal to the voltage times the charge. Each gram of lithium represents Faraday's constant / 6.941(atomic mass), or 13,901 coulombs. At 3 V, this gives 41.7 kJ per gram of lithium, or 11.6 kWh per kilogram of lithium. This is slightly more than the heat of combustion of gasoline; however, lithium-ion batteries as a whole are still significantly heavier per unit of energy due to the additional materials used in production. Note that the cell voltages involved in these reactions are larger than the potential at which an aqueous solutions would electrolyze.

== Television rights == The domestic broadcasting rights for the competition were held by the BBC, who had held them since the 2014–15 season, and ITV, who were showing matches for the second successive season. Both of these broadcasters will air the tournament until the 2024–25 season, and both were permitted to show the final live. In addition, FA Cup matches could also be streamed on ESPN+.

A surface charge is an electric charge present on a two-dimensional surface. These electric charges are constrained on this 2-D surface, and surface charge density, measured in coulombs per square meter (C•m−2), is used to describe the charge distribution on the surface. The electric potential is continuous across a surface charge and the electric field is discontinuous, but not infinite; this is unless the surface charge consists of a dipole layer. In comparison, the potential and electric field both diverge at any point charge or linear charge. In physics, at equilibrium, an ideal conductor has no charge on its interior; instead, the entirety of the charge of the conductor resides on the surface. However, this only applies to the ideal case of infinite electrical conductivity; the majority of the charge of an actual conductor resides within the skin depth of the conductor's surface. For dielectric materials, upon the application of an external electric field, the positive charges and negative charges in the material will slightly move in opposite directions, resulting in polarization density in the bulk body and bound charge at the surface. In chemistry, there are many different processes which can lead to a surface being charged, including adsorption of ions, protonation or deprotonation, and, as discussed above, the application of an external electric field. Surface charge emits an electric field, which causes particle repulsion and attraction, affecting many colloidal properties.

Chemokine (C-X-C motif) ligand 7 (CXCL7) is a human gene. The encoded protein, Chemokine (C-X-C motif) ligand is a small cytokine belonging to the CXC chemokine family. It is an isoform of Beta-Thromboglobulin or Pro-Platelet basic protein (PPBP). It is a protein that is released in large amounts from platelets following their activation. It stimulates various processes including mitogenesis, synthesis of extracellular matrix, glucose metabolism and synthesis of plasminogen activator.

Sources: en.wikipedia.org

Supporting material

The binding of ibotenic acid allows excess Ca2+ into the system which results in neuronal cell death. Ca2+ also activates CaM-KII or Ca2+/Calmodulin Kinase which phosphorylates multiple enzymes. The activated enzymes then begin producing reactive oxygen species which damages surrounding tissue. The excess Ca2+ results in the enhancement of the mitochondrial electron transport system which will further increase the number of reactive oxygen species.

In castrated immature male rats, vosilasarm (at 10 mg/kg/day orally, the highest assessed dose) maximally stimulated prostate weight to 67%, seminal vesicle weight to 59%, and levator ani muscle weight to 117% compared to that induced with testosterone propionate 1 mg/kg/day. Moreover, when combined with testosterone propionate, vosilasarm partially antagonized the weight increases of the prostate gland and seminal vesicles, reducing them to 84% and 78% (both from 100%), respectively. Conversely however, the combination of testosterone propionate and vosilasarm was additive in terms of levator ani muscle weight stimulation, increasing it to 124%. Vosilasarm was found to stimulate muscle at a dose much lower than that required to stimulate the prostate. A dose of 0.3 mg/kg/day stimulated levator ani muscle weight to a similar extent relative to the levator ani weight in non-castrated controls. Conversely, a 33-fold higher dose of 10 mg/kg/day was required to stimulate prostate weight to a similar extent as that in non-castrated controls. Similarly, in gonadally intact immature rats, 0.3 mg/kg/day vosilasarm stimulated levator ani muscle weight to a similar extent as testosterone propionate 0.5 mg/kg/day, but a dose of 30 mg/kg/day (100-fold higher) was required to stimulate the prostate to a similar extent as testosterone propionate 0.5 mg/kg/day.

=== Portal: The Uncooperative Cake Acquisition Game === A board game version of Portal, developed by Cryptozoic Entertainment with oversight from Valve, was released in 2015. Titled Portal: The Uncooperative Cake Acquisition Game, the game tasks players with manipulating their tokens—representing unwitting test subjects—through various test chambers in Aperture Laboratories. The primary goal is to acquire cake slices by successfully navigating subjects through the chambers. The basic gameplay loop involves moving subjects toward the opposite end of the board's tiles. These tiles are slowly recycled and moved back to the start, making the board function like a conveyor belt. When a tile is recycled at the end of the track, the player with the most subjects on that tile receives its associated rewards. Players must then protect their acquired cake slices from opponents, who can attempt to dispose of them by recycling the test chambers they reside in or by incinerating them using action cards. Additionally, the game features portals for faster movement, a Weighted Companion Cube that distracts subjects and prevents reward acquisition on its occupied tile, and a turret that eliminates all subjects on its tile. The game ends when a player runs out of either test subjects or cake slices, at which point the player with the most accumulated cake slices is declared the winner. In the event of a tie, the tied player with the most remaining test subjects wins.

== History == Cyclic guanosine monophosphate (cGMP) research began after cGMP and cyclic adenosine monophosphate (cAMP) were identified as cellular components and potentially involved with cellular regulation. Upon the synthesis of cGMP in 1960, progress rapidly spread in the understanding of regulation and effects of cGMP. Earl W. Sutherland received the 1971 Nobel Prize in Medicine for his work with cAMP and secondary messengers. This award sparked extensive research into cAMP, while cGMP received less attention, with its biological functions largely unknown until the 1980s. During this period, two pivotal discoveries highlighted cGMP's role in cellular signaling: atrial natriuretic peptide (ANP) was found to stimulate cGMP synthesis through the particulate guanylyl cyclase (pGC) receptor, and nitric oxide (NO), identified as the endothelium-derived relaxing factor, was shown to activate soluble guanylyl cyclase (sGC), producing cGMP to mediate vasodilation in smooth muscle cells. Further components involved with the cGMP were also identified such as cGMP-hydrolyzing phosphodiesterases (PDEs) and cGMP-binding proteins. The awarding of the 1998 Nobel Prize to Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad for their discoveries in the NO-cGMP pathway renewed interest in cGMP research with the 1st International Conference on cGMP being held in 2003.

In both cases, Oedipus can therefore be recognized as a "liminal" or threshold figure, helping effect the transition between the old religious practices, represented by the death of the Sphinx, and the rise of the new, Olympian gods.

Sources: en.wikipedia.org

Supporting material

== Treatment == Prednisone is usual drug for PMR, and treatment frequently lasts for more than a year. If the patient does not experience dramatic improvement after three days of 10–20 mg oral prednisone per day, the diagnosis should be reconsidered. Sometimes relief of symptoms occurs in only several hours. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen are ineffective in the initial treatment of PMR, but they may be used in conjunction with the maintenance dose of corticosteroid. Along with medical treatment, patients are encouraged to exercise and eat healthily, helping to maintain a strong immune system and build strong muscles and bones. A diet of fruits, vegetables, whole grains, and low-fat meat and dairy products, avoiding foods with high levels of refined sugars and salt is recommended. Research in the UK has also suggested that people with polymyalgia rheumatica would benefit from a falls assessment when first diagnosed, and regular treatment reviews.

A countercurrent multiplication loop is a system where fluid flows in a loop so that the entrance and exit are at similar low concentration of a dissolved substance but at the far end of the loop there is a high concentration of that substance. A buffer liquid between the incoming and outgoing tubes receives the concentrated substance. The incoming and outgoing tubes do not touch each other. The system allows the buildup of a high concentration gradually, by allowing a natural buildup of concentration towards the tip inside the in-going tube, (for example using osmosis of water out of the input pipe and into the buffer fluid), and the use of many active transport pumps each pumping only against a very small gradient, during the exit from the loop, returning the concentration inside the output pipe to its original concentration. The incoming flow starting at a low concentration has a semipermeable membrane with water passing to the buffer liquid via osmosis at a small gradient. There is a gradual buildup of concentration inside the loop until the loop tip where it reaches its maximum. Theoretically a similar system could exist or be constructed for heat exchange. In the example shown in the image, water enters at 299 mg/L (NaCl / H2O). Water passes because of a small osmotic pressure to the buffer liquid in this example at 300 mg/L (NaCl / H2O). Further up the loop there is a continued flow of water out of the tube and into the buffer, gradually raising the concentration of NaCl in the tube until it reaches 1199 mg/L at the tip.

Tuttle (1857), first bishop of the Episcopal Diocese of Idaho, Montana, and Utah William David Walker (1859), first bishop of the Episcopal Diocese of North Dakota Henry Y. Satterlee (1863), first bishop of the Episcopal Diocese of Washington; established the Washington National Cathedral Bernard Drachman (1882), leader of Orthodox Judaism; former president of the Orthodox Union Leon Harrison (1886), rabbi of Temple Israel in St. Louis Herbert Shipman (1890), Suffragan bishop in the Episcopal Diocese of New York Stephen Samuel Wise (1892), rabbi and Zionist leader Frederick Herbert Sill (1895), Anglican monk and founder of the Kent School Henry S. Whitehead (1904), rector, and author of horror fiction Vedder Van Dyck (1918), fifth bishop in the Episcopal Diocese of Vermont Walter M. Higley (1922), sixth bishop of the Episcopal Diocese of Central New York M. Moran Weston (1930), Episcopal priest, social activist, and businessman who co-founded Carver Federal Savings Bank Arthur Lelyveld (1933), rabbi, president of the American Jewish Congress and first Jewish editor-in-chief of the Columbia Daily Spectator Moshe Davis (1936), rabbi and founder of Camp Ramah Paul van K.

=== Clinical laboratory === On 3 October 2013, a special ceremony was held at the Sindh Institute of Urology and Transplantation (SIUT) Chablani Medical Center to dedicate its clinical laboratory in memory of Tanveer Abbasi a renowned writer, poet and intellectual of Sindh.

require that the partial double bond be broken, so that the activation energy is roughly 80 kJ/mol (20 kcal/mol). However, the activation energy can be lowered (and the isomerization catalyzed) by changes that favor the single-bonded form, such as placing the peptide group in a hydrophobic environment or donating a hydrogen bond to the nitrogen atom of an X-Pro peptide group. Both of these mechanisms for lowering the activation energy have been observed in peptidyl prolyl isomerases (PPIases), which are naturally occurring enzymes that catalyze the cis-trans isomerization of X-Pro peptide bonds. Conformational protein folding is usually much faster (typically 10–100 ms) than cis-trans isomerization (10–100 s). A nonnative isomer of some peptide groups can disrupt the conformational folding significantly, either slowing it or preventing it from even occurring until the native isomer is reached. However, not all peptide groups have the same effect on folding; nonnative isomers of other peptide groups may not affect folding at all.

Sources: en.wikipedia.org

Frequently asked questions

Why are clinical results inconsistent?

Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.

In which countries is thymosin alpha 1 approved?

Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.

How is the peptide characterized in review articles?

Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.

How should a dissolved solution be kept?

Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.

Network